Multispecific antibodies and uses thereof
Anti-CLEC5A antibodies with enhanced Fc receptor binding and specific CDR sequences provide potent phagocytic activity with low cytokine release, addressing the limitations of existing CLEC5A therapeutics for diseases like cancer and autoimmune disorders.
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- LTZ THERAPEUTICS INC
- Filing Date
- 2026-06-17
- Publication Date
- 2026-07-09
AI Technical Summary
Current therapeutics targeting CLEC5A, a type II transmembrane protein expressed on myeloid lineages, fail to effectively mediate phagocytosis of target cells with minimal cytokine release, limiting their efficacy and safety profile in treating diseases associated with CLEC5A activation.
Development of anti-CLEC5A antibodies and antigen-binding fragments with enhanced binding affinity to FcγRIIa and FcγRIIIa receptors, capable of mediating potent phagocytosis and target cell killing by myeloid cells with low cytokine release, utilizing specific CDR sequences and Fc modifications.
The antibodies achieve high target cell killing efficacy with minimal cytokine release, offering a safer and more effective therapeutic approach for conditions like cancer and autoimmune diseases.
Smart Images
Figure 00000208_0000 
Figure 00000209_0000 
Figure 00000209_0001